Tvardi Therapeutics, Inc. (TVRD)
1.78
-0.04
(-2.20%)
USD |
NASDAQ |
Aug 26, 16:00
1.79
+0.01
(+0.56%)
Pre-Market: 20:00
Tvardi Therapeutics PS Ratio
PS Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical PS Ratio Data
| Date | Value |
|---|---|
| March 28, 2025 | 7.919 |
| March 27, 2025 | 8.273 |
| March 26, 2025 | 8.50 |
| March 25, 2025 | 8.326 |
| March 24, 2025 | 8.642 |
| March 21, 2025 | 8.765 |
| March 20, 2025 | 7.919 |
| March 19, 2025 | 8.042 |
| March 18, 2025 | 7.996 |
| March 17, 2025 | 7.873 |
| March 14, 2025 | 7.888 |
| March 13, 2025 | 7.781 |
| March 12, 2025 | 7.857 |
| March 11, 2025 | 7.880 |
| March 10, 2025 | 7.550 |
| March 07, 2025 | 7.565 |
| March 06, 2025 | 7.442 |
| March 05, 2025 | 6.920 |
| March 04, 2025 | 6.812 |
| March 03, 2025 | 7.119 |
| February 28, 2025 | 7.35 |
| February 27, 2025 | 7.427 |
| February 26, 2025 | 7.688 |
| February 25, 2025 | 7.704 |
| February 24, 2025 | 7.704 |
| Date | Value |
|---|---|
| February 21, 2025 | 7.642 |
| February 20, 2025 | 7.873 |
| February 19, 2025 | 7.719 |
| February 18, 2025 | 7.750 |
| February 14, 2025 | 7.996 |
| February 13, 2025 | 8.611 |
| February 12, 2025 | 8.073 |
| February 11, 2025 | 7.919 |
| February 10, 2025 | 7.750 |
| February 07, 2025 | 7.688 |
| February 06, 2025 | 7.873 |
| February 05, 2025 | 7.750 |
| February 04, 2025 | 7.550 |
| February 03, 2025 | 7.35 |
| January 31, 2025 | 7.442 |
| January 30, 2025 | 7.704 |
| January 29, 2025 | 7.673 |
| January 28, 2025 | 7.473 |
| January 27, 2025 | 8.319 |
| January 24, 2025 | 9.211 |
| January 23, 2025 | 7.781 |
| January 22, 2025 | 7.35 |
| January 21, 2025 | 7.073 |
| January 17, 2025 | 7.150 |
| January 16, 2025 | 7.073 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PS Ratio Benchmarks
| Eli Lilly & Co. | 13.56 |
| Nektar Therapeutics | 32.78 |
| Crinetics Pharmaceuticals, Inc. | 200.73 |
| Liquidia Corp. | 15.39 |
| ANI Pharmaceuticals, Inc. | 1.645 |
PS Ratio Related Metrics
| Price to Book Value | 1.992 |
| Price | 1.78 |
| Earnings Yield | -156.1% |
| Market Cap | 16.70M |